



WHOLELIFE
PHARMACY & HEALTHFOODS

2026 WHOLELIFE Awards



Congratulations TO OUR SUPPLIER PARTNER WINNERS



SUPPLIER OF THE YEAR AWARD

MOOGOO



PROFESSIONAL SERVICES SUPPLIER OF THE YEAR AWARD

ARROTEX
PHARMACEUTICALS



MEDICINES SUPPLIER OF THE YEAR

KENVUE



NATURAL HEALTH SUPPLIER OF THE YEAR AWARD

TRUE PROTEIN



BEAUTY & PERSONAL CARE SUPPLIER OF THE YEAR AWARD

MOOGOO



HEALTH FOOD SUPPLIER OF THE YEAR AWARD

BIO LIVING

Congratulations to our **RETAIL STORE WINNERS**



STORE OF THE YEAR AWARD

MENAI

WholeLife Pharmacy
& Healthfoods



PHARMACIST OF THE YEAR AWARD

EMILY LARCOMBE

Atherton
WholeLife Pharmacy
& Healthfoods



RETAIL MANAGER OF THE YEAR AWARD

ERIN GENEROWICZ

Redlynch
WholeLife Pharmacy
& Healthfoods



SPOTLIGHT AWARD

MADELINE BENTO

Highfields
WholeLife Pharmacy
& Healthfoods



EXCELLENCE IN BUSINESS GROWTH AWARD

MAROOCHYDORE
WholeLife Pharmacy
& Healthfoods



EXCELLENCE IN BUSINESS GROWTH AWARD

LAWLER'S DEE WHY
WholeLife Pharmacy
& Healthfoods



EXCELLENCE IN BUSINESS GROWTH AWARD

HERVEY BAY
WholeLife Pharmacy
& Healthfoods



COMMUNITY CHAMPION AWARD

HERVEY BAY
WholeLife Pharmacy
& Healthfoods



BEST MERCHANDISING AWARD

CAIRNS CENTRAL
WholeLife Healthfoods
Markets

Today's issue of PD

Pharmacy Daily today features three pages of news, plus a front cover page from **WholeLife Pharmacy & Healthfoods**.

WholeLife awards

WHOLELIFE Pharmacy & Healthfoods held its 2026 Gala Evening last night, recognising the outstanding achievements of individuals and teams across the WholeLife group.

Supplier of the Year was awarded to MooGoo Skin Care, which also took out Beauty and Personal Care Supplier of the Year.

Emily Larcombe from Atherton WholeLife Pharmacy & Wholefoods was awarded Pharmacist of the Year, and Store of the Year went to Menai WholeLife.

See all the winners on the [cover page](#).

Guild Foundation teams up with Vinnies

THE Pharmacy Guild of Australia is set to launch the Pharmacy Guild Foundation, an initiative designed to improve access to essential medicines and pharmacy care for vulnerable, disadvantaged and underserved communities, with Vinnies - St Vincent de Paul Society NSW - named as its inaugural partner.

The Foundation will officially launch on 10 Sep with an inaugural Gala Dinner at Sydney's Fullerton Hotel, held in conjunction with Pharmacy Connect 2026.

Building on almost 100 years of community pharmacy's service to Australians, chair of the Pharmacy Guild Foundation, Catherine Bronger, said the Foundation was a natural extension of the values that have always underpinned community pharmacy.

"Pharmacists have always cared deeply about the communities they serve," Bronger said.

"Every day, we see health challenges firsthand and work

with patients to help them achieve better outcomes.

"The Foundation provides an opportunity for our profession to give back in a different way, supporting individuals, families and communities who are facing significant health and social disadvantage."

In the last financial year, St Vincent de Paul Society NSW provided support for almost 2,500 people with scripts and medical help, with an average of \$130 in assistance per person.

St Vincent de Paul Society NSW acting executive director of membership, volunteers and early intervention, Joy Kyriacou, said the partnership reflected a shared commitment to helping those most in need.

"St Vincent de Paul Society NSW has a proud history of supporting people facing hardship and disadvantage with dignity, compassion and practical assistance.

"We are delighted to work



alongside community pharmacy to deliver this important work," Kyriacou said.

The Foundation will focus on funding projects to improve access to essential medicines and healthcare services for vulnerable communities while supporting sustainable pharmacy services and workforce capability in underserved regions.

"Our vision is simple: to harness the generosity, expertise and community spirit of pharmacy to help improve lives and create a healthier community and a healthier future for all Australians," Bronger concluded.

Book tickets and learn more [HERE](#).

Don't suffer the pain of toothache.

Available from Symbion, Sigma, API & CH2

Always read the label and follow the directions for use.




For the temporary relief of pain from toothache.



Mag-Sup®

Australia's No.1 magnesium product.*

Available in
50's, 100's, 250's, 500's
and **200g oral powder.**



NOW AVAILABLE IN 500's

Always read the label and follow the directions for use.

*Mag-Sup is the No.1 Magnesium product in the Vitamins category in Australian Pharmacy in terms of Retail unit sales. IQVIA™, Pharmacy, VMS category, Total Units, 52 weeks, WE_2024-02-12

Available from Symbion, Sigma, API & CH2. Pharmacy only.



PBS listing for Zoladex alternative

AT A special meeting to consider changing the Pharmaceutical Benefits Scheme (PBS) listing for triptorelin (Diphereline, Ipsen), the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing be made unrestricted, opening the door to its use across a number of women's health conditions.

A gonadotrophin-releasing hormone agonist, the triptorelin 3.75mg injection is currently PBS-listed to treat hormone-dependent locally advanced or metastatic prostate cancer.

While also used to treat several women's health conditions, including breast cancer, endometriosis and fibroids, it is not PBS-listed for these and would cost up to \$264 per month.

The PBAC special meeting came about after AstraZeneca announced it would pull its low-

dose Zoladex (goserelin 3.6mg) from the Australian market in Nov this year, although it has since advised it will continue to supply the medication for free to patients without suitable treatment pathways (PD 20 Jul).

AstraZeneca is also seeking regulatory and PBS reimbursement approval to make the 10.8mg Zoladex implant available for hormone receptor-positive breast cancer patients.

The PBAC recommended a review of triptorelin 3.75mg utilisation be completed around two years after the amendment to the PBS listing to determine whether there are any changes to the expected utilisation.



RIPAA joins forces with rural allies

THE Remote and Isolated Pharmacist Association Australia (RIPAA) has formally joined the National Rural Health Alliance (NRHA), a coalition of 57 national member organisations that aim to ensure health policy reflects the operational and clinical realities of practice beyond major regional hubs.

RIPAA President Fredrik Hellqvist highlighted the importance of aligning national health policy with the practical needs of rural and remote practitioners and the communities they serve.

"We are proud to join the National Rural Health Alliance to contribute a grounded, realistic voice on healthcare delivery outside major population centres," Hellqvist said.

"Whether embedded in local community pharmacies or broader health teams, our members strive to act as vital partners in primary healthcare networks - working



alongside local GPs, aged care providers, Aboriginal Community Controlled Health Services, and rural health teams.

"However, sustaining these collaborative clinical roles in thin markets is an uphill battle under current funding settings.

"Without dedicated support, providing services beyond standard dispensing is becoming increasingly unviable," he added.

Hellqvist noted that while Australia's current regulatory and funding arrangements help ensure that community pharmacies remain physically present and accessible in rural and remote communities, the role of pharmacy extends well beyond the supply of medicines.

"Ensuring residents in rural, remote and isolated thin markets have ongoing access to comprehensive, professional health services requires tailored, fit-for-purpose funding frameworks" he said.

"By working within the Alliance, RIPAA looks forward to collaborating with fellow health peak bodies to support innovative primary care models, workforce sustainability, and funding solutions that address market failure and reflect the true dynamics of operating across MM 4-7 communities," he concluded.

CSL posts \$3.63b loss in "reset year", but positioned for growth

IN FY26 results posted this morning, CSL has reported a US\$2.6 billion (A\$3.63 billion) loss, its first loss since listing as a public company in 1994.

While total revenue was only slightly down on last year at US\$15.8 billion, the bottom line was dealt a savage blow by restructuring costs of US\$800 million and pre-tax impairments of more than US\$7 billion.

In a message to investors, chairman Dr Brian McNamee acknowledged the company was

"slow to adapt to competitive pressures, our research and development efforts didn't deliver and some investments the company made did not perform".

Interim CEO Brian Naylor called FY26 "a year of reset", highlighting progress on its transformation program, simplification of the business, and investment in commercial capabilities and development programs that will drive top line growth in the future.

Meanwhile plasma market

fundamentals and demand remain strong, and there is growing momentum behind some of CSL's newer therapies.

CSL anticipates revenue in FY27 to be steady, with underlying net profit forecast to grow by approximately 5%.

CSL Behring expects mid-single digit revenue growth, and CSL Seqirus expects low single digit revenue growth as immunisation rates in the US are expected to drop, albeit at a slower rate than recent years.

Sleep Deeper. Wake Refreshed.

While reducing the time
taken to fall asleep.



MagZorb® SLEEP

LEARN MORE

Available via Symbion, API & CH2

Always read the label and follow the directions for use.



Dispensary Corner

IN GOOD news for mums, it seems that dads may be to blame for babies' chunky thighs and jelly belly - a course set in motion before conception.

Researchers from Brazil found that the more ultra-processed food a father ate, the heavier the baby was at birth, with more fat in their thighs and the "love-handle" regions.

While everyone loves a cuddly baby, those born heavy are more likely to develop diseases like heart disease, type 2 diabetes, and certain types of cancer later in life.

Researchers believe it's down to epigenetics, with ultra-processed foods feeding inflammation, affecting sperm, and changing which genes are switched on or off in the baby.

In this case, the gene in question is IGF-II, which is inherited from the father only, and is responsible fetal growth.

"Maternal nutrition and health before, during, and after the baby's birth have always received attention, but little is said about the role of the father's diet," study co-author Daniela Sartorelli said.

"Our study shows that it also matters a great deal for the baby's health."

CW shines spotlight on brands



CHEMIST Warehouse recently held its 2026 brand showcase event, CW Brand Lab, in Melbourne, welcoming more than 600 media, talent and content creators from across Australia, alongside 1,710 consumers, for one of the biggest events on the Australian beauty, health and wellness calendar.

More than 80 brands spanning cosmetics, skincare, haircare, fragrance, wellness, health and parenting came together to showcase their products.

Guests experienced immersive brand activations, new product launches and sampling, gamification, personalised experiences, beauty services, engraving, a nail bar, themed food and drinks, DJs, giveaways and content moments.

The event also featured a dedicated Ultra Beauty moment, with brands including The Ordinary, IT Cosmetics, Tir Tir and Anua.

"What started in 2022 has grown into one of the most anticipated events on our calendar, with our brands, media, talent and customers genuinely looking forward to it each year," Alexandra Bateman, head of PR and events at Chemist Warehouse, said.

"At its core, the brand showcase is about creating a powerful platform for our supplier partners to bring their brands to life, to tell their stories, launch new products, create engaging content and connect directly with some of Australia's most influential media and creators, as well as the consumers who shop with us every day," she added.

TGA in peptide, melanotan raids

THE Therapeutic Goods Administration (TGA) has seized more than \$120,000 of illicit peptide and anabolic steroid products from NSW residential premises allegedly linked to a social media influencer.

The influencer allegedly imported and relabelled products including retatrutide, CJC-1295 and the Wolverine Stack (combination of BPC-157 and TB-500) before advertising and selling them on various social media platforms and a dedicated website.

The influencer had been previously warned by the TGA.

The TGA reiterated its warning that influencers, affiliates, online sellers and anyone else promoting unapproved peptide products may be held accountable for unlawful advertising and should ensure they understand their legal obligations.

MEANWHILE, the regulator also seized nasal spray products it suspected contained Melanotan II, with lab testing confirming its presence in concentrations that varied between bottles.

A NSW-based person was fined a total of over \$101,000 for the alleged unlawful supply of Melanotan II products to Australian consumers.



The Evolution of **stirlingFILDES**

A Multi-Channel Pharmacy Growth Platform built on 90 years of trusted foundations.

Wholesale Distribution | Brand Fostering | Retail Activation | Marketing | Logistics



www.pharmacydaily.com.au

Pharmacy Daily is part of the Business Publishing Group family of publications.

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL

Editor - Karina Bray
Journalists - Adam Bishop, Myles Stedman, Janie Medbury, James Bale
Editor-at-large - Bruce Piper
Associate Publisher - Jo-Anne Hui-Miller
Editorial Director - Damian Francis

ADVERTISING AND MARKETING

Head of Sales & Marketing - Sean Harrigan
Business Development Manager - Kara Stanley
advertising@pharmacydaily.com.au

GENERAL MANAGER & PUBLISHER

Matthew Vince

ACCOUNTS

accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd
Macquarie Park NSW 2113 Australia
Tel: 1300 799 220 (+61 2 8007 6760)

info@pharmacydaily.com.au



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Damian Francis.